STOCK TITAN

CureVac N.V. - CVAC STOCK NEWS

Welcome to our dedicated news page for CureVac N.V. (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CureVac N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CureVac N.V.'s position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.78%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
covid-19
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.42%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.47%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
earnings
CureVac N.V.

Nasdaq:CVAC

CVAC Rankings

CVAC Stock Data

678.49M
118.65M
45.43%
23.79%
2.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Tuebingen

About CVAC

founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o